BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17391492)

  • 1. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.
    Golshayan AR; Jin T; Maciejewski J; Fu AZ; Bershadsky B; Kattan MW; Kalaycio ME; Sekeres MA
    Br J Haematol; 2007 Apr; 137(2):125-32. PubMed ID: 17391492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.
    Sekeres MA; Fu AZ; Maciejewski JP; Golshayan AR; Kalaycio ME; Kattan MW
    Cancer; 2007 Mar; 109(6):1125-32. PubMed ID: 17265521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
    Hui CH; Horvath N; Lewis I; To LB; Szabo F
    Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
    Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
    Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
    Chen SC; Jiang B; Da WM; Gong M; Guan M
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
    Fenaux P
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
    Wimazal F; Germing U; Kundi M; Noesslinger T; Blum S; Geissler P; Baumgartner C; Pfeilstoecker M; Valent P; Sperr WR
    Cancer; 2010 May; 116(10):2372-81. PubMed ID: 20209617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
    Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
    Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
    Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
    Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
    J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.